These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 22868799)

  • 21. Applicability of somatic monitoring instructions in clinical practice guidelines on antipsychotic drug use.
    Brouwer JMJL; Olde Hengel E; Risselada AJ; van Roon EN; Mulder H
    BMC Psychiatry; 2021 Apr; 21(1):189. PubMed ID: 33845804
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Essential pharmacokinetic information for drug dosage decisions: a concise visual presentation in the drug label.
    Menon-Andersen D; Yu B; Madabushi R; Bhattaram V; Hao W; Uppoor RS; Mehta M; Lesko L; Temple R; Stockbridge N; Laughren T; Gobburu JV
    Clin Pharmacol Ther; 2011 Sep; 90(3):471-4. PubMed ID: 21796114
    [No Abstract]   [Full Text] [Related]  

  • 23. Web-based intensive monitoring: from passive to active drug surveillance.
    Härmark L; van Grootheest K
    Expert Opin Drug Saf; 2012 Jan; 11(1):45-51. PubMed ID: 22007719
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drug selection errors in relation to medication labels: a simulation study.
    Garnerin P; Perneger T; Chopard P; Arès M; Baalbaki R; Bonnabry P; Clergue F
    Anaesthesia; 2007 Nov; 62(11):1090-4. PubMed ID: 17924887
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Short communication: a study on the packaging information of essential drug products used at Union and Thana health complex level in Bangladesh.
    Amran S; Ahmed M; Shaheen SM; Morshed SN; Khandakar J; Rahman M; Rahman M; Hossain A
    Pak J Pharm Sci; 2007 Oct; 20(4):327-32. PubMed ID: 17604258
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacogenomic biomarkers in drug labels: what do they tell us?
    Tutton R
    Pharmacogenomics; 2014 Feb; 15(3):297-304. PubMed ID: 24533709
    [TBL] [Abstract][Full Text] [Related]  

  • 27. How pharmacogenomics (PG) are changing practice: implications for prescribers, their patients, and the healthcare system (PG series part I).
    Preskorn SH; Hatt CR
    J Psychiatr Pract; 2013 Mar; 19(2):142-9. PubMed ID: 23507814
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Consistency in the safety labeling of bioequivalent medications.
    Duke J; Friedlin J; Li X
    Pharmacoepidemiol Drug Saf; 2013 Mar; 22(3):294-301. PubMed ID: 23042584
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Baseline and follow-up laboratory monitoring of cardiovascular medications.
    Tjia J; Fischer SH; Raebel MA; Peterson D; Zhao Y; Gagne SJ; Gurwitz JH; Field TS
    Ann Pharmacother; 2011 Sep; 45(9):1077-84. PubMed ID: 21852593
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Availability of Spanish prescription labels: a multi-state pharmacy survey.
    Bailey SC; Pandit AU; Curtis L; Wolf MS
    Med Care; 2009 Jun; 47(6):707-10. PubMed ID: 19433992
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Therapeutic drug monitoring in pregnancy.
    Matsui DM
    Ther Drug Monit; 2012 Oct; 34(5):507-11. PubMed ID: 22846897
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Medication safety: just a label away.
    Jennings J; Foster J
    AORN J; 2007 Oct; 86(4):618-25. PubMed ID: 17931541
    [TBL] [Abstract][Full Text] [Related]  

  • 33. How should ethnicity-related information be included on drug labels? Considerations based on comparison of multiregional clinical trial data on the label between Japan and the United States.
    Tanaka A; Asano K; Uyama Y
    Clin Pharmacol Ther; 2015 Nov; 98(5):480-2. PubMed ID: 26250551
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rationalizing the use of auxiliary label for oral oncology drugs.
    Ng T; Badry N; de Lemos ML
    J Oncol Pharm Pract; 2017 Jul; 23(5):338-343. PubMed ID: 27208015
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A cross-national comparison of 17 countries' insulin glargine drug labels.
    Polinski JM; Kesselheim AS; Seeger JD; Connolly JG; Choudhry NK; Shrank WH
    Pharmacoepidemiol Drug Saf; 2015 Feb; 24(2):159-65. PubMed ID: 25250724
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Whither therapeutic drug monitoring?
    Doogue MP; Martin JH
    Intern Med J; 2010 Oct; 40(10):671-2. PubMed ID: 20958899
    [No Abstract]   [Full Text] [Related]  

  • 37. Health literacy assessment of labeling of pediatric nonprescription medications: examination of characteristics that may impair parent understanding.
    Yin HS; Parker RM; Wolf MS; Mendelsohn AL; Sanders LM; Vivar KL; Carney K; Cerra ME; Dreyer BP
    Acad Pediatr; 2012; 12(4):288-96. PubMed ID: 22579032
    [TBL] [Abstract][Full Text] [Related]  

  • 38. How effective is [corrected] the use of DBS and DPS as tools to encourage widespread therapeutic drug monitoring?
    Baietto L; Simiele M; D'Avolio A
    Bioanalysis; 2014 Feb; 6(4):425-7. PubMed ID: 24568344
    [No Abstract]   [Full Text] [Related]  

  • 39. Evaluation of a pharmacist-managed amiodarone monitoring program.
    Spence MM; Polzin JK; Weisberger CL; Martin JP; Rho JP; Willick GH
    J Manag Care Pharm; 2011 Sep; 17(7):513-22. PubMed ID: 21870892
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A System for Anesthesia Drug Administration Using Barcode Technology: The Codonics Safe Label System and Smart Anesthesia Manager.
    Jelacic S; Bowdle A; Nair BG; Kusulos D; Bower L; Togashi K
    Anesth Analg; 2015 Aug; 121(2):410-21. PubMed ID: 24859078
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.